Esophageal stricture

GIE Medical Launches Two Clinical Trials to Investigate Use of a Multi-Stage Drug Coated Balloon in Esophageal and Bowel Strictures

Retrieved on: 
Tuesday, December 13, 2022
Paclitaxel, Quality of life, Patient, United, TTS, Mayo Clinic, Health, Colon, Safety, Rectum, Treatment, Esophageal stricture, Dysphagia, Stricture, DCB, Pharmaceutical industry, Esophagus

The second, PAclitaxel Coated Balloon for the Treatment of Chronic bEnigN sTricture - Bowel (PATENT-B) , is a study to evaluate the safety and efficacy of ProTractX3™ DCB for the treatment of benign bowel strictures.

Key Points: 
  • The second, PAclitaxel Coated Balloon for the Treatment of Chronic bEnigN sTricture - Bowel (PATENT-B) , is a study to evaluate the safety and efficacy of ProTractX3™ DCB for the treatment of benign bowel strictures.
  • Several patients have already been treated in these trials, and active enrollment will continue throughout the U.S.
  • It is an investigational device in the U.S.
    GIE Medical is a clinical stage company conducting trials in the U.S. to help patients suffering from benign stricture(s) of the esophagus or bowel (small intestine, colon, and rectum).
  • The ProTractX3™ Through the Scope Drug Coated Balloon could offer a new solution for treating GI strictures, potentially creating sustained long-term patency and reducing the number of treatments.